Group 1 - The company, Lijing Pacific (00575.HK), announced that it will hold a board meeting on August 27, 2025, to approve the interim results for the six months ending June 30, 2025, and to consider the payment of an interim dividend, if any [1]

董事會會議日期 勵晶太平洋集團有限公司(「本公司」)董事會(「董事會」)謹此宣佈本公司將於 二零二五年八月二十七日(星期三)舉行董事會會議，藉以(其中包括)批准本公司及 其附屬公司截至二零二五年六月三十日止六個月之中期業績及其發佈，以及考慮 派付中期股息 (如有)。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容而產生或因倚賴該等內容而引致之任 何損失承擔任何責任。 執行董事： Jamie Gibson （行政總裁） 非執行董事： James Mellon （主席） Jayne Sutcliffe 獨立非執行董事： Mark Searle 陳弘俊 Ihsan Al Chalabi 承董事會命 勵晶太平洋集團有限公司 執行董事 Jamie Gibson 香港，二零二五年八月十五日 於本公佈日期，董事會包括六名董事： ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 勵晶太平洋集團有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 第 1 頁 共 11 頁 v 1.1.1 每股面值 0.001 美元之未分類股份，可發行為普通股或每股面值 0.001 美元之無投票權可換股遞延股份 FF301 第 2 頁 共 11 頁 v 1.1.1 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00575 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 143,000,000,000 | USD | | 0.001 USD | | 143,000,000 | | 增加 / 減少 (-) | | | 0 ...

Deep Longevity, Inc(本公司之一家全资附属公司，Deep Longevity)于本年度上半年在新客户拓展方面持 续取得进展，其中值得注意 的新客户包括中国香港的仁山医疗(https://www.humansahealth.com)及印度 的Holistica World (https://www.holisticaworld.com)。此外，与去年同期相比，本年度上半年客户对Deep Longevity的老化时钟的使用量有所增加，显示了技术的价值，以及长寿及保健作为一种健康趋势日益 受到关注。Deep Longevity旨在与采用B2C模式的长寿应用程式、其他平台、初创企业以及诊断公司建 立新的合作伙伴关系。 Deep Longevity致力于最大的长寿市场美国(美国)推出老化时钟，并委聘一名美国总裁领导该市场的拓 展工作，相信这将推动业务增长。值得注意的是，虽然长寿与保健市场仍处于发展初期，但此项独特的 技术旨在进入这个极为庞大且不断成长的市场，估算该市场于2023年的价值超过6.3万亿美元。 Deep Longevity拥有活跃的渠道，目前正与巴西、德国及东南亚等市场的多间长寿诊所及其他 ...

Summary of Key Points Core Viewpoint - As of April 30, a total of 43 stocks reached their 52-week highs, with notable performers including 廸生创建 (00113), 励晶太平洋 (00575), and 东方企控集团 (00018) achieving high rates of 17.01%, 13.73%, and 12.79% respectively [1]. 52-Week Highs - 廸生创建 (00113) closed at 6.840 with a peak of 6.880, marking a 17.01% increase [1]. - 励晶太平洋 (00575) reached a closing price of 0.970 and a high of 1.160, reflecting a 13.73% rise [1]. - 东方企控集团 (00018) had a closing price of 0.385 and a maximum of 0.485, showing a 12.79% increase [1]. - Other notable stocks include 茂盛控股 (00022) at 10.53%, and ＴＣＬ电子 (01070) at 8.70% [1]. 52-Week Lows - 中国疏浚环保 (00871) recorded a significant drop, closing at 0.098 with a low of 0.050, resulting in a -26.47% decline [2]. - 瑞和数智 (03680) fell to 0.330 with a low of 0.325, indicating a -12.16% change [2]. - 济丰包装 (01820) closed at 4.000, reaching a low of 3.500, which is a -12.06% decrease [2]. - Other companies experiencing declines include 中国卫生集团 (00673) at -8.97% and 亚太金融投资 (08193) at -6.56% [2].

Financial Performance - The Company reported a reduced loss attributable to shareholders of approximately US$4.48 million, primarily due to operating and R&D expenses of approximately US$4.99 million[2]. - The Group recorded a reduced loss attributable to shareholders of approximately US$4.48 million in 2024, down from US$25.05 million in 2023[15][34]. - Total revenue for 2024 was US$656,000, compared to a loss of US$539,000 in 2023, indicating a significant improvement[34]. - The operating loss after impairment losses and provisions for 2024 was US$4.34 million, a decrease from US$30.38 million in 2023[34]. - Revenue for the year ended December 31, 2024, increased to US$0.72 million, a 148.28% increase from US$0.29 million in 2023[191]. - Other income rose to US$0.08 million, reflecting a 166.67% increase from US$0.03 million in the previous year[191]. - Total loss attributable to shareholders decreased to US$4.48 million for the year ended December 31, 2024, an 82.12% reduction from US$25.05 million in 2023[191]. - Capital deficiency increased to approximately US$5.90 million as of December 31, 2024, up from approximately US$1.55 million as of December 31, 2023[194]. - The Group recorded no amortization of intangible assets for the year ended December 31, 2024, compared to US$22.18 million in 2023[198]. - The Group's income tax credit for the year ended December 31, 2024, was approximately US$26,000, a 99.45% decrease from US$5.42 million in 2023[198]. Product Development and Market Strategy - Wanbang Biopharmaceutical submitted the NDA to NMPA at the end of 2024, with approval expected within 12 months, and upon approval, the Group expects to receive US$5 million and an additional US$2 million upon first commercial sale of Senstend™ in China[2][7]. - The manufacturing and supply agreement was signed between Wanbang Biopharmaceutical, Genetic S.p.A., and Plethora Solutions Limited for the production of Senstend™ for the PRC market[2]. - The rights to Fortacin™ were out-licensed to Kobayashi Pharmaceutical Co., Ltd. for the Japanese market[2][7]. - The Company has completed the evaluation of two proposals for Phase 3 clinical studies of Fortacin™ in the US[2]. - The potential market for Senstend™ in China is approximately 9 million patients in its first year, growing to over 170 million patients by its tenth year[8]. - The Company is focused on the successful commercialization of Fortacin™/Senstend™ in key markets including China, the US, and Japan[4][5]. - The Company aims to commercialize its deep learning aging clock technology and partner with clinics and insurance companies[4][5]. - Deep Longevity is integrating its AI-led deep learning technology to build and commercialize various aging clocks[6]. - The Group aims to improve its financial performance and reduce losses in the upcoming fiscal year, as indicated by the significant decrease in losses reported[189]. Financial Position and Assets - Total assets decreased from US$80,310,000 in 2020 to US$610,000 in 2024, representing a decline of approximately 99.24%[37]. - Current liabilities increased significantly from US$9,105,000 in 2020 to US$5,649,000 in 2024, indicating a rise of about 62.5%[37]. - The Group's net liabilities reached US$5,901,000 in 2024, compared to net assets of US$50,305,000 in 2020, marking a substantial shift in financial position[37]. - The Group's current assets dropped from US$12,790,000 in 2021 to US$601,000 in 2024, a decrease of approximately 95.3%[37]. - The Group's intangible assets were fully impaired, decreasing from US$72,418,000 in 2020 to zero in 2024[37]. Corporate Governance and Compliance - The Group has complied with relevant laws and regulations that significantly impact its operations, ensuring adherence to applicable standards[42]. - The Group's financial risk management objectives and policies are detailed in the consolidated financial statements, indicating a structured approach to managing financial uncertainties[38]. - The company has applied all principles of the Corporate Governance Code and complied with applicable provisions during the year ended December 31, 2024[100]. - All directors have confirmed compliance with the Securities Dealing Code and the Model Code during the year ended December 31, 2024[99]. - The company has a strong governance structure with experienced professionals in key management positions, including a Chartered Secretary and a Chartered Governance Professional[188]. Share Options and Capital Structure - As of December 31, 2024, the total issued ordinary share capital consisted of 228,438,619 shares, unchanged from the previous year[55]. - The Share Option Scheme (2016) allows for 2,456,532 options available for grant as of December 31, 2024[64]. - No options were granted or exercised during the year ended December 31, 2024[65]. - The total number of options vested/unvested as of December 31, 2024, was 6,229,723[68]. - The company has not experienced any lapsing or cancellation of options during the year ended December 31, 2024[87]. - As of December 31, 2024, the company's distributable reserves amounted to approximately US$294 million, unchanged from 2023[88]. Leadership and Management - Jamie Alexander Gibson has been the CEO since May 2002, focusing on corporate finance and emerging market investment products[172]. - Jayne Allison Sutcliffe co-founded the Group in 1990 and has extensive experience in fund management, previously serving as Group Chief Executive of Charlemagne Capital Limited[175]. - Stawell Mark Searle has over 30 years of experience in investment management and has been an Independent Non-Executive Director since October 2001[175]. - Adrian Alan Chan has over 25 years of experience in accounting and financial management, serving as CFO for multiple companies including Enviro Energy International Holdings Limited[176][179]. - The management team includes experienced professionals such as Paul Eric Jones, who has over 30 years in the energy industry and corporate finance, and Michael Grant Wyllie, who has over 30 years in the pharmaceutical industry[185]. - The leadership team includes directors with diverse backgrounds in finance, law, and investment management, enhancing strategic decision-making[176][179]. Auditor and Financial Reporting - The Company has appointed RSM Hong Kong as the new auditor effective from June 21, 2023, following the resignation of BDO Limited[158]. - The company announced the resignation of RSM as the external auditor effective from July 16, 2024, due to a disagreement on the audit fee for the financial year ending December 31, 2024[162]. - Baker Tilly Hong Kong Limited was appointed as the new auditor effective from July 16, 2024, to fill the vacancy left by RSM, with a term until the next annual general meeting tentatively scheduled for June 2025[163]. - The consolidated financial statements for the year ended December 31, 2024, have been audited by Baker Tilly, which has expressed its willingness to continue in office and will seek re-appointment at the 2025 AGM[164]. - The Audit Committee reviewed RSM's audit fee proposal and deemed it inappropriate considering the current operational scale of the group and prevailing market rates[162].

Financial Performance - The company's loss attributable to shareholders significantly decreased to approximately $4,480,000, primarily due to operational and R&D expenses of about $4,990,000[2]. - Revenue for the year ended December 31, 2024, was $719,291,000, compared to $291,000,000 in 2023, representing a significant increase[12]. - Operating loss decreased to $4,337,000 in 2024 from $27,713,000 in 2023, indicating improved operational efficiency[12]. - Net loss for the year was $4,482,000, a reduction from $25,049,000 in the previous year, reflecting better financial performance[13]. - Basic and diluted loss per share improved to $(1.96) in 2024 from $(11.13) in 2023, suggesting a positive trend in shareholder value[13]. - The group reported a loss of approximately $4,482,000 for the year ending December 31, 2024[29]. - The company reported a pre-tax loss of $4,508,000 for the year 2024, compared to a pre-tax loss of $30,463,000 in 2023[42]. - The company reported a significant reduction in loss attributable to shareholders, amounting to approximately $4.48 million for the year ended December 31, 2024, compared to $25.05 million for the year ended December 31, 2023, representing an 82.12% decrease[56]. - Revenue increased by 148.28% to $0.72 million in 2024 from $0.29 million in 2023[58]. - Other income rose by 166.67% to $0.08 million in 2024 from $0.03 million in 2023[58]. Research and Development - Research and development expenses were reduced to $938,000 in 2024 from $1,379,000 in 2023, showing a focus on cost management[12]. - The company is engaged in investments in biopharmaceutical companies and other corporate investments, indicating a strategic focus on growth sectors[16]. - Jiangsu Wanbang Pharmaceutical submitted a new drug application to the National Medical Products Administration, with expectations for approval within 12 months, potentially generating $5,000,000 (pre-tax) upon receiving the import license for Senstend™[2][4]. - The company has licensed Fortacin™ to Kobayashi Pharmaceutical Co., Ltd. for the Japanese market and is finalizing the budget for Phase III clinical trials in the U.S.[4][5]. - The group is in discussions with two well-known clinical research organizations regarding the third-phase clinical study of Fortacin™ in the U.S.[64]. - The company expects to recognize approximately $52,000 in revenue from remaining performance obligations under existing contracts within the next year, up from $10,000 in 2023[45]. Operational Efficiency and Strategy - The company aims to enhance operational efficiency and continue its commitment to sustainable development practices[11]. - Future strategic focuses include seeking commercial partnerships for licensing Fortacin™ rights in the U.S. and supporting Jiangsu Wanbang in the commercialization of new drug applications[11]. - The overall business performance in 2024 is viewed positively, reflecting the team's hard work and commitment to sustainable growth[8][9]. - The company maintains a cautiously optimistic outlook for the upcoming year while remaining vigilant about geopolitical and macroeconomic uncertainties[9]. - The group is implementing operational plans to control costs and generate sufficient operating cash flow to meet current and future obligations[31]. Financial Position and Liabilities - Total current assets decreased to $601,000 in 2024 from $2,785,000 in 2023, indicating a potential liquidity concern[14]. - Total liabilities increased to $5,901,000 in 2024 from $1,551,000 in 2023, highlighting a rise in financial obligations[15]. - The company's current liabilities and total liabilities were approximately $5,048,000 and $5,901,000, respectively, as of December 31, 2024[102]. - The company’s capital deficit increased from approximately $1.55 million as of December 31, 2023, to approximately $5.90 million as of December 31, 2024, primarily due to the loss attributable to shareholders[59]. - There is significant uncertainty regarding the group's ability to continue as a going concern, depending on the success of its plans and measures[32]. Shareholder and Corporate Governance - The company did not declare or recommend any dividends for the year ended December 31, 2024, consistent with 2023[51]. - The board has resolved not to declare a final dividend for the year ending December 31, 2024, consistent with the previous year[94]. - The company has adhered to the corporate governance code throughout the fiscal year ending December 31, 2024[95]. - The board and senior management are actively involved in strategic planning, focusing on long-term value creation and short-term priorities[75]. - The company is committed to returning shareholder value through value-accretive acquisitions and effective dividend policies[77]. Auditor and Compliance - The independent auditor, Tianzhi, confirmed that the financial statements for the year ending December 31, 2024, were prepared in accordance with Hong Kong Financial Reporting Standards[101]. - The board appointed Tianzhi as the new auditor effective July 16, 2024, following the resignation of Roshan Mei due to disagreements over audit fees[97]. - Roshan Mei resigned as the auditor effective July 16, 2024, after failing to reach an agreement on audit fees for the year ending December 31, 2024[97]. - The annual report for the year ending December 31, 2024, will be available by the end of April 2025[103]. Market Potential and Growth - Senstend™ is projected to initially target around 9 million patients in China, with potential growth to over 170 million patients by the tenth year[6]. - The market for aging solutions, driven by Deep Longevity's AI technology, is valued at over $6 trillion, indicating significant growth potential[6]. - The company continues to have confidence in Deep Longevity, which is a pioneer in its field, utilizing machine learning through the SenoClock® SaaS platform to determine biological age and provide longevity recommendations[73]. - The company is optimistic about its business outlook for 2025, with plans to submit a new drug application to the National Medical Products Administration and assist Jiangsu Wanbang Pharmaceutical in commercializing Senstend™ in China, which is expected to generate a significant milestone payment of $7,000,000[72].

Financial Performance - The Company reported a loss attributable to shareholders of approximately US$2.62 million for the six months ended 30 June 2024, a significant reduction from approximately US$12.20 million for the same period in 2023[12]. - Revenue decreased by 29.41% to US$0.12 million compared to US$0.17 million in the previous year[12]. - The Group recorded a capital deficiency of approximately US$4.07 million as of 30 June 2024, primarily due to the loss attributable to shareholders[6]. - Plethora recorded an operating loss of approximately GBP 210,000 (or approximately US$266,000) for the six months ended 30 June 2024, compared to an operating loss of approximately GBP 345,000 (or approximately US$426,000) for the same period in 2023[16]. - The company reported a loss for the period of US$2,621,000 for the six months ended June 30, 2024, compared to a loss of US$12,199,000 for the same period in 2023[52]. - The total comprehensive loss for the period was US$2,609,000 for the six months ended June 30, 2024, indicating a continued trend of financial losses[51]. - The Group's loss before tax for the six months ended June 30, 2024, was $2,621,000[80]. - The Group reported a loss attributable to shareholders of US$2,621,000 for the six months ended 30 June 2024, compared to a loss of US$12,199,000 for the same period in 2023[99]. - The total segment loss for the Biopharma segment was $655,000, while the Corporate Investment segment reported a loss of $1,902, leading to a total loss of $2,557,000 for the Group[80]. Revenue and Income - Revenue for the six months ended June 30, 2024, was reported at US$126,000, a decrease of 32.9% compared to US$188,000 for the same period in 2023[72]. - Royalty income for the period was US$80,000, slightly down from US$82,000 in the previous year, representing a decrease of 2.4%[72]. - Income generated from the Deep Longevity segment was US$43,000 from implementation services, up from US$42,000, while subscription and support services generated no income compared to US$11,000 in 2023[72]. - The geographical breakdown of revenue showed that Europe contributed $86,000, the US $12,000, and Asia Pacific $25,000 for the Biopharma segment in the first half of 2024[85]. Assets and Liabilities - The Group's liabilities included trade payables and other payables of approximately US$3.16 million, long-term and short-term lease liabilities of approximately US$0.97 million, and long-term shareholder's loans of US$0.72 million[16]. - The Group's assets included cash and bank balances of approximately US$0.28 million and property, plant, and equipment of approximately US$0.41 million[16]. - As of June 30, 2024, the net current liabilities increased to US$2,830,000 from US$796,000 as of December 31, 2023, indicating a significant rise in short-term financial obligations[47]. - The net liabilities increased to US$4,074,000 as of June 30, 2024, up from US$1,551,000 at the end of 2023, showing a worsening financial position[48]. - The equity attributable to shareholders decreased to US$228,000 as of June 30, 2024, with accumulated losses rising to US$309,060,000 from US$306,439,000[51]. Research and Development - The Company is evaluating two proposals from clinical research organizations for Phase 3 clinical studies of Fortacin™ in the US[8]. - R&D expenditure decreased by 23.19% to US$0.53 million from US$0.69 million in the previous year[12]. - The main objective for Senstend™ in the PRC is to submit the NDA to NMPA by the end of 2024, with approval expected 12 months thereafter[18]. - Wanbang Biopharmaceutical will cover all costs of clinical trials and associated regulatory submission costs for Senstend™[22]. Corporate Developments - The Group has out-licensed the rights of Fortacin™ to Kobayashi Pharmaceutical Co., Ltd. for Japan as of 26 July 2024[9]. - A manufacturing and supply agreement was signed with Genetic S.p.A. for Senstend™ to be supplied to Wanbang Biopharmaceutical for the Chinese market[9]. - The signing of the manufacturing and supply agreement for Senstend™ is expected to facilitate the NDA registration process with the NMPA[18]. - The company announced a licensing agreement with Kobayashi Pharmaceutical Co., Ltd. for the commercialization of FortacinTM in Japan, with potential payments of up to US$1.55 million and a double-digit percentage royalty[170]. - The company entered into a manufacturing and supply agreement with Wanbang Biopharmaceutical for the production of Senstend™ in the PRC, with an initial term of five years[171]. Cash Flow and Financing - Net cash used in operating activities was US$2,555,000 for the first half of 2024, slightly higher than US$2,367,000 in the prior year[54]. - The company generated net cash of US$216,000 from investing activities, a decrease from US$830,000 in the same period last year[56]. - Net cash generated from financing activities was US$509,000, down from US$5,757,000 in the previous year, primarily due to a decrease in net proceeds from rights issues[56]. - The Company entered into a loan agreement with Galloway for a total loan facility of US$2,000,000 at an interest rate of 8% per annum, with US$720,000 drawn down as of June 30, 2024, and an additional US$655,000 drawn post the interim period[58]. - Material uncertainty exists regarding the Group's ability to continue as a going concern, dependent on successful drawdown of the Galloway Loan, completion of fundraising by a subsidiary, and effective cost control measures[59]. Shareholder Information - The company has resolved not to declare an interim dividend for the six months ended June 30, 2024, consistent with the previous year[32]. - The basic loss per share for the six months ended 30 June 2024 was 1.148 US cents, a decrease from 5.501 US cents in the prior year[99]. - The total number of outstanding options as of 30 June 2024 was 6,729,723, with a weighted average exercise price of HK$2.287[155]. - The total number of issued shares as of June 30, 2024, was 228,392,286 shares[191]. - The company has not granted any options to directors, chief executives, or substantial shareholders during the reporting period[161]. Governance and Compliance - The company is committed to maintaining high standards of corporate governance as outlined in the CG Code[177]. - The Company has complied with the Code Provisions set out in the CG Code for the six months ended 30 June 2024[179]. - The Board consists of six Directors, including one Executive Director (CEO), two Non-Executive Directors, and three Independent Non-Executive Directors[179]. - The Audit Committee, Remuneration Committee, and Nomination Committee assist the Board in overseeing management and business performance[179]. - The Board is responsible for evaluating and determining the nature and extent of risks acceptable to achieve the Group's strategic objectives, maintaining an effective risk management and internal control system[199].

Financial Performance - The company reported a loss attributable to shareholders of approximately $2,620,000 for the six months ended June 30, 2024, primarily due to operational and R&D expenses of about $2,610,000[1]. - Capital loss recorded by the group was approximately $4,070,000, mainly driven by the loss attributable to shareholders[1]. - Revenue for the six months ended June 30, 2024, was $123,000, a decrease of 29% compared to $173,000 in the same period of 2023[4]. - Operating loss for the period was $2,557,000, significantly improved from an operating loss of $15,063,000 in the previous year[4]. - The company reported a total comprehensive loss of $2,609,000 for the period, compared to $12,134,000 in the same period of 2023[5]. - The company reported a net loss attributable to shareholders of $(2,621,000) for the six months ended June 30, 2024, compared to $(12,199,000) for the same period in 2023[26]. - The basic loss per share for the six months ended June 30, 2024, was $(1.148), compared to $(5.501) for the same period in 2023[26]. - For the six months ended June 30, 2024, the company reported a significant reduction in loss attributable to shareholders to approximately $2.62 million, compared to $12.20 million for the same period in 2023, representing a decrease of 78.52%[33]. - Total revenue for the six months ended June 30, 2024, was $0.12 million, a decrease of 29.41% from $0.17 million in the same period of 2023[33]. - The company recorded an operating loss of approximately $2.56 million for the six months ended June 30, 2024, compared to an operating loss of $30.38 million for the same period in 2023[33]. Assets and Liabilities - The net cash and bank balances decreased to $280,000 from $2,097,000 as of December 31, 2023[6]. - As of June 30, 2024, the company's current liabilities and total liabilities were approximately $2,830,000 and $4,074,000, respectively[10]. - The company’s net asset value per share was reported at -$1.78, compared to -$0.68 in the previous year[8]. - The company’s capital deficit increased from approximately $1.55 million as of December 31, 2023, to approximately $4.07 million as of June 30, 2024, primarily due to the loss attributable to shareholders[35]. - The company’s total liabilities include approximately $3.16 million in trade payables and other payables, and approximately $970,000 in lease liabilities[35]. - Trade payables amounted to $13,000 as of June 30, 2024, compared to $102,000 as of December 31, 2023[28]. - The total liabilities, including lease liabilities, were $4,346,000 as of December 31, 2023[18]. - The total assets classified as held for sale amounted to $2,794,000 as of December 31, 2023[18]. Revenue Generation - Revenue from patent licensing was $80,000, a slight decrease from $82,000 in the previous year[13]. - The company generated $123,000 in revenue from external customers in the biopharmaceutical segment for the six months ended June 30, 2024[15]. - Revenue from external customers in the biopharmaceutical segment was $173,000 for the six months ended June 30, 2023[17]. Research and Development - Fortacin™ is undergoing evaluation for a Phase III clinical study in the U.S. with two renowned clinical research institutions[2]. - The company has licensed Fortacin™ to Kobayashi Pharmaceutical Co., Ltd. in Japan and signed a manufacturing and supply agreement with Genetic S.p.A. for Senstend™ in China[2]. - Research and development expenses related to the Fortacin™ approval process in the U.S. amounted to approximately £144,000 (or about $183,000) for the six months ended June 30, 2024[36]. - The company anticipates submitting a new drug application for Senstend™ to the National Medical Products Administration in China by the end of 2024, with a potential payment of $5,000,000 upon approval[1]. Future Plans and Outlook - The company plans to implement cost control measures and timely collection of receivables to improve cash flow[11]. - The company is considering fundraising arrangements to meet its funding needs[11]. - There is significant uncertainty regarding the company's ability to continue as a going concern, dependent on successful loan extraction and fundraising efforts[11]. - The company maintains an optimistic outlook for the second half of 2024, focusing on submitting a new drug application for Senstend™ in China and starting Phase III studies in the U.S.[49]. Corporate Governance and Management - The company has adhered to corporate governance codes and maintains high standards of corporate governance[60]. - The company has appointed a new auditor, Lo & Co., effective June 21, 2023, following the resignation of its previous auditor[63]. - The company appointed RSM Hong Kong as the new auditor effective from June 21, 2023, to fill the vacancy left by the resignation of Hong Kong Lee & Associates[64]. - The company has a total of 17 employees and 2 consultants as of June 30, 2024, down from 20 employees and 1 consultant six months prior[59]. Dividends and Securities - The company did not declare or pay any interim dividends for the six months ended June 30, 2024[24]. - The company has not repurchased, sold, or redeemed any of its listed securities during the six months ending June 30, 2024[65]. - The company has not declared an interim dividend for the six months ending June 30, 2024[48]. Strategic Partnerships and Agreements - The company has established a manufacturing and supply agreement with Jiangsu Wanbang Pharmaceutical for the production and supply of Senstend™ in China, with an initial term of five years[31]. - Jiangsu Wanbang Pharmaceutical will pay the company $5 million upon receiving import approval for Senstend™ and an additional $2 million after the first commercial sale in China[37]. - The company anticipates milestone payments of up to $25 million based on net sales achieved by Jiangsu Wanbang Pharmaceutical[38]. - The company has licensed Fortacin™ to Kobayashi Pharmaceutical Co., Ltd. in Japan, receiving a signing fee of $500,000[41]. Risk Management - The company emphasizes the importance of risk management related to its interests in Plethora and Deep Longevity[54]. - The capital debt ratio is considered meaningless due to capital losses as of June 30, 2024[53]. - There are no significant contingent liabilities as of June 30, 2024[55]. Other Information - The interim report for the six months ending June 30, 2024, will be available by the end of September 2024[67]. - The company did not make any significant acquisitions or disposals of subsidiaries in the six months ending June 30, 2024[57]. - Deep Longevity plans to launch the SenoClock® platform in China, India, and Australia in Q3 2024, aiming to increase revenue and visibility[42]. - The company is in discussions with major insurance companies and a Fortune 500 consumer health company for pilot studies, which could lead to significant revenue opportunities[43]. - The company is updating its blood age algorithm to meet stricter clinical guidelines, leveraging large language models for enhanced personalization[44].

Financial Performance and Projections - The company recognized a full impairment of right-of-use assets due to continuous losses and negative cash flow from its biopharmaceutical and corporate investment businesses, resulting in a recoverable amount of zero[4]. - Estimated proceeds from the sale of listed securities in 2024 are projected to be $297,000, while proceeds from the sale of an associate company are expected to be $1,130,000[5]. - The company anticipates milestone revenue from China to reach $5,000,000 in 2025, with royalty income estimated at $500,000[5]. - The revenue growth rate for royalty income is conservatively estimated between 0% and 17%, while income from intellectual property (Deep Longevity) is projected to grow between 33.7% and 115.2%[5]. - Revenue projections for Deep Longevity are estimated at $458,000 in 2024, $1,396,800 in 2025, $2,220,200 in 2026, and $3,235,400 in 2027, with a growth rate of 45.7% to 205.0%[7]. - The company adjusted its revenue growth rate from a previous range of 63.9%-366.7% down to 45.7%-205.0% due to actual cash flows being approximately 59% lower than prior forecasts[8]. - The total operating expenses are projected to range from -133.6% to -52.6%[7]. Impairment and Valuation - The impairment assessment for intangible assets, specifically the intellectual property of Deep Longevity, indicated a valuation of approximately $1,670,000 against a book value of $1,520,000, suggesting no impairment is necessary[6]. - The valuation method used for intangible assets is the income approach, which quantifies future earnings into expected future cash flows[10]. - The company acknowledged a full impairment after discussions with Rosenblatt regarding revenue growth rates and actual income per customer, leading to projected net cash outflows during the forecast period[11]. Business Strategy and Focus - The company has shifted its business focus from B2C to B2B, leading to adjustments in the cash flow forecast period from ten years to four years, aligning with the remaining useful life of the intangible assets[8]. - The supplementary information provided does not affect other data contained in the 2023 annual report, which remains unchanged[11].